Bladder preservation trial for muscle-invasive bladder cancer with variant histology
Part of Cancer clinical trials.
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have muscle-invasive bladder cancer with a variant histology type.
- Your cancer should be at stage cT2 to cT4 and not have spread to lymph nodes or distant organs.
- You must have had a TURBT procedure and a CT scan of your chest, abdomen, and pelvis, or a PET scan to confirm your diagnosis.
- You must be willing to give written informed consent and follow the study requirements.
- You cannot have diffuse CIS (a widespread type of carcinoma in situ) in your pathology report.
- You cannot have hydronephrosis (kidney swelling) on both sides, only one side is allowed if present.
- You must not have had radiation therapy to your pelvis before.
- You must not have had systemic therapy (like chemotherapy) for muscle-invasive bladder cancer before.
- You cannot have another active cancer, unless it was treated more than 5 years ago and you have no evidence of disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.
This trial tests a combination of two drugs, sacituzumab govitecan and zimberelimab, to treat muscle-invasive bladder cancer without removing the bladder. It's for patients who cannot or choose not to have bladder removal surgery or standard chemotherapy.
This study compares two ways to check if bladder cancer has grown into the muscle layer: an MRI scan (mpMRI) versus a standard surgery called TURBT (where a small tool removes a sample of the tumor). The goal is to see if the MRI can be as accurate as the surgery, so future patients might avoid an extra procedure.
This study looks at a treatment approach called trimodality therapy (TMT) that aims to save the bladder in people with high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to standard treatments or have had multiple recurrences. It offers an alternative to bladder removal surgery.
This study follows people with muscle-invasive bladder cancer who choose to keep their bladder (instead of removing it) after receiving chemotherapy, immunotherapy, or an ADC drug. It aims to see how well this approach works and what side effects may occur.
This trial studies a bladder-sparing treatment plan that uses MRI to guide therapy for muscle-invasive bladder cancer. It combines maximal tumor removal, chemotherapy, and radiation to avoid bladder removal.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.